Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Deficiency in neuronal TGF-β signaling promotes neurodegeneration and Alzheimer’s pathology
Ina Tesseur, … , Eliezer Masliah, Tony Wyss-Coray
Ina Tesseur, … , Eliezer Masliah, Tony Wyss-Coray
Published November 1, 2006
Citation Information: J Clin Invest. 2006;116(11):3060-3069. https://doi.org/10.1172/JCI27341.
View: Text | PDF
Research Article Neuroscience

Deficiency in neuronal TGF-β signaling promotes neurodegeneration and Alzheimer’s pathology

  • Text
  • PDF
Abstract

Alzheimer’s disease (AD) is characterized by progressive neurodegeneration and cerebral accumulation of the β-amyloid peptide (Aβ), but it is unknown what makes neurons susceptible to degeneration. We report that the TGF-β type II receptor (TβRII) is mainly expressed by neurons, and that TβRII levels are reduced in human AD brain and correlate with pathological hallmarks of the disease. Reducing neuronal TGF-β signaling in mice resulted in age-dependent neurodegeneration and promoted Aβ accumulation and dendritic loss in a mouse model of AD. In cultured cells, reduced TGF-β signaling caused neuronal degeneration and resulted in increased levels of secreted Aβ and β-secretase–cleaved soluble amyloid precursor protein. These results show that reduced neuronal TGF-β signaling increases age-dependent neurodegeneration and AD-like disease in vivo. Increasing neuronal TGF-β signaling may thus reduce neurodegeneration and be beneficial in AD.

Authors

Ina Tesseur, Kun Zou, Luke Esposito, Frederique Bard, Elisabeth Berber, Judith Van Can, Amy H. Lin, Leslie Crews, Patrick Tremblay, Paul Mathews, Lennart Mucke, Eliezer Masliah, Tony Wyss-Coray

×

Figure 4

Inhibition of endogenous TGF-β signaling increases neuritic degeneration and Aβ production in neuroblastoma cells.

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of endogenous TGF-β signaling increases neuritic degeneration...
(A) Transient transfection of TβRIIΔk and a TGF-β reporter plasmid (p800 luciferase) into B103-APPwt cells dose-dependently inhibited signaling 24 hours after transfection. (B) Quantification of the percentage of B103-APPwt cells transiently transfected with TβRIIΔk that showed healthy (black), beaded (white), or no processes (gray) 12 hours after transfection. (C) Expression of TβRIIΔk in B103-APPwt (APPwt) or B103 cells lacking APP (neo) significantly reduced the percentage of cells with healthy processes 12 and 36 hours after transfection. (D–F) Downstream inhibition of TGF-β signaling via treatment with 1 μM SB505124 (D) or expression of dominant-negative Smad3 (Smad3DN; E) reduced the percentage of cells with healthy processes 36 hours after treatment. (F) Expression of constitutively active Smad3 (Smad3CA) partially rescued the phenotype in cells coexpressing TβRIIΔk. (G) B103-APPwt cells expressing TβRIIΔk showed beading and retraction of neurites (12 h), followed by rounding up of the cell body (36 h). Control cells were transfected with filler plasmid and GFP. Scale bar: 50 μm. *P < 0.05, **P < 0.01 versus respective controls; Student’s t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts